the product in the database has an inactive status
indications:
The drug is indicated for the initiation and / or continuation of cervical dilation in pregnant women at the time of delivery (from 38 weeks of gestation), when the following conditions are met: cervical condition assessed according to the Bishop scale for 6 or fewer points; single pregnancy; the head position of the fetus; it is advisable to give birth; no contraindications from the mother or the fetus.
Composition:
1 vaginal therapeutic system contains 10 mg of dinoprostone (5 mg / 12 h).
Action:
Dinoprostone - prostaglandin E2 - it has a strong stimulating effect on the smooth muscles of the pregnant uterus, leading to uterine contractions and acceleration of cervical maturation. Within 12 hours, about 5 mg of dinoprostone are released.
Contraindications:
Hypersensitivity to prostaglandins or other components of the preparation. The product should not be used or immediately discontinued: after starting the delivery; after the rupture of the membranes; when oxytocin is used; in conditions where prolonged uterine contraction is not recommended (ie in patients after extensive uterine surgical procedures, after cervical surgery, significant maternal incontinence, abnormal fetal position, suspected or symptomatic fetal distress, with difficult or traumatic delivery in the interview, after at least three deliveries on time); after a previous or co-existing inflammatory disease within the pelvic region; in the case of multiple pregnancy.
Precautions:
Caution should be exercised when using the preparation in patients with a history of uterine contraction and in patients with glaucoma or bronchial asthma. Before using prostaglandin E2 should be discontinued non-steroidal anti-inflammatory drugs and analgesics. Intensified and prolonged uterine contractions may precede tetanus or uterine rupture, so the insert should be removed immediately. The insert should be removed immediately from the vagina if cervical dilatation is complete or in the following circumstances: after starting labor (after application of the preparation, the occurrence of regular, painful uterine contractions occurring every 3 minutes, regardless of whether in the cervix there are changes); after spontaneous or caused by artificially ruptured membranes; if there is a suspicion of excessive uterine stimulation and excessive spasms; when signs of fetal distress occur; if you have side effects of the medicine; when oxytocin is planned.
Pregnancy and lactation:
The preparation is intended for use only in pregnant women at the time of delivery, when there are indications for induction of labor.
Side effects:
Common side effects usually following vaginal administration of prostaglandin E have been observed following administration2. There are reports of deviations in CTG and non-specific fetal distress states during and after vaginal prostaglandin E2. Excessive frequency and intensity of uterine contractions have been observed, sometimes with a threat to the fetus, which requires immediate removal of the vaginal insert. Gastrointestinal effects were observed: nausea, vomiting, diarrhea.
Dosage:
Intravaginal: 1 insert. This amount is usually sufficient to achieve a full dilatation of the cervix; if the insert is not fully open within 8-12 hours, the insert should be removed, it can be replaced with the Next insert, which should be removed at the latest after a further 12 hours (2 intravaginal inserts every 12 hours constitute the maximum recommended dose). The insert should be placed deeply into the posterior vagina, using a small amount of water-soluble lubricant. Then turn it 90 degrees so that it is placed transversely in the posterior vault of the vagina.
(C)
